킴스온라인

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Society for Medical Oncology (ESMO) Congress 2025

17 October - 21 October, 2025, Germany

ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC

2025-11-03

Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

2025-11-03

First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.
ICON8B OS data support a new SoC for epithelial ovarian cancer

2025-11-03

In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.
Nivolumab bests ipilimumab in head-to-head melanoma trial

2025-11-03

The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Enzalutamide-ADT a win for biochemically recurrent prostate cancer

2025-11-03

In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

주요메뉴

최근 본 콘텐츠